# Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02172807** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 201 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium low
- **DRUG:** Tiotropium high
- **DRUG:** Placebo MDI
- **DRUG:** Placebo inhalation capsule
- **DRUG:** Oxitropium

## Key facts

- **NCT ID:** NCT02172807
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2001-09
- **Final completion:** —
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02172807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02172807, "Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02172807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*